Who is sponsoring NCT05362942?

NCT05362942 is sponsored by Beijing 302 Hospital.

What drugs are being tested in NCT05362942?

Interventions in NCT05362942: Venetoclax, Decitabine, Azacytidine, Cytarabine.

What condition does NCT05362942 study?

NCT05362942 studies Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease.

Is NCT05362942 still recruiting?

NCT05362942 is currently status unknown. Last updated 5 May 2022.

Last reviewed 2022-05-05 · How we verify

NCT05362942

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Status unknown Phase 2 Last updated 5 May 2022

What this trial tests

Phase 2 trial testing Venetoclax, Decitabine, Azacytidine, Cytarabine in Relapsed Acute Myeloid Leukemia in 52 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
30 April 2023

30 April 2024

Quick facts

Lead sponsor	Beijing 302 Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	1 May 2022
Primary completion	30 April 2023
Estimated completion	30 April 2024

Drugs / interventions tested

Venetoclax, Decitabine, Azacytidine, Cytarabine — full drug profile →

Conditions studied

Relapsed Acute Myeloid Leukemia — all drugs for Relapsed Acute Myeloid Leukemia →
Refractory Acute Myeloid Leukemia — all drugs for Refractory Acute Myeloid Leukemia →
Minimal Residual Disease — all drugs for Minimal Residual Disease →

Sponsor

Beijing 302 Hospital

Who can join

18 and older, any sex, with Relapsed Acute Myeloid Leukemia or Refractory Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although studies are ongoing to evaluate the efficiency and safety of venetoclax-based therapy, alone or in combination with hypomethylation agent or low-dose cytarabine, in relapsed/refractory acute myeloid leukemia, data are scarce and heterogenous. In this study, the investigators aimed to assess safety and response to a new venetoclax-based triple-drug combination regimen (venetoclax + hypomethylation agent + low-dose cytarabine) in acute myeloid leukemia patients who had relapsed/refractory disease or positive minimal residual disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.
Angotzi F, Lessi F, Leoncin M, Filì C, et al · · 2024 · cited 8× · PMID 38680863 · DOI 10.3389/fonc.2024.1370405
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.
Koolivand Z, Bahreini F, Rayzan E, Rezaei N. · · 2025 · cited 3× · PMID 39811307 · DOI 10.1016/j.heliyon.2024.e41355

Verify or expand the search:

Other recruiting trials for Relapsed Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT06741722 — Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML · Phase 2 · recruiting
NCT06536959 — VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS · Phase 2 · recruiting
NCT06017258 — A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia · Phase 1 · recruiting
NCT04797767 — Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms · Phase 1, PHASE2 · recruiting

Other Beijing 302 Hospital trials

Trials by the same sponsor.

NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05362942 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
Last refreshed: 5 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05362942.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing